CKD-M2 study: 2-year mortality prediction tool for advanced kidney disease
The updated prediction tool demonstrated satisfactory performance in both internal and external validation processes. Before it can be used in clinical practice, it must undergo national and international external validations, which are currently in progress.
Authors
- Peggy Perrin (ORCID: https://orcid.org/0000-0001-7343-5943)
- Yves Dimitrov (ORCID: https://orcid.org/0000-0002-5029-7872)
- Zead Tubail (ORCID: https://orcid.org/0009-0005-6746-6790)
- François Chantrel
- JP Fauvel
- Michel Ducher
- Dung N. T. Tran
- Denis Fouque
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Centre National de la Recherche Scientifique (FR)
- Hospices Civils de Lyon (FR)
- Centre Hospitalier De Pau (FR)
- Hôpital Lyon Sud (FR)
- Centre Hospitalier Régional de Metz-Thionville (FR)
- Laboratoire de recherche en cardiovasculaire, métabolisme, diabétologie et nutrition (FR)
- Laboratoire de Biométrie et Biologie Evolutive (FR)
- Groupe Hospitalier de la Région de Mulhouse et Sud Alsace (FR)
- Université de Strasbourg (FR)
Publication Details
- Journal
- BMC Nephrology
- Published
- 2025-12-25
- DOI
- https://doi.org/10.1186/s12882-025-04715-x
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- GlaxoSmithKline
- Institut National de la Santé et de la Recherche Médicale
- Astellas Pharma
- Servier